CLOV · Clover Health Investments, Corp.
AI read · Neutral
The AI's read
A target is UBS's estimate, not a new company result. Keeping the Neutral rating shows the firm did not change its overall view.
UBS raised its price target for Clover Health Investments to $5.50, up from $5.00.
Neutral
UBS raised its target for Clover Health, but kept its Neutral rating. The higher estimate is favorable, but the unchanged rating leaves no clear shift in the company's outlook.
Get alerts for CLOV
Follow Clover Health Investments, Corp. (CLOV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CLOVFree on the App Store and Google Play, or on the web.